Institut Bordet - Retour à la page d'accueil
en
I want to donate to research

Philippe Aftimos

Department : Medical oncology, Clinical Trials Conduct Unit (CTCU)
 
philippe.aftimos [at] bordet.be

Publications

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.

Authors : Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P
Year : 2019
Journal : Lancet Oncol

EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.

Authors : Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG
Year : 2019
Journal : Future Oncol

Lucitanib for the treatment of HR<sup>+</sup>/ HER2<sup>-</sup> metastatic breast cancer: results from the multicohort phase II FINESSE study.

Authors : Hui R, Pearson A, Cortés J, Campbell C, Poirot C, Azim HA, Fumagalli D, Lambertini M, Daly F, Arahmani A, Pérez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, Curigliano G
Year : 2019
Journal : Clin Cancer Res

Extended time interval between diagnosis and surgery does not improve the outcome in patients operated for resection or ablation of breast cancer liver metastases.

Authors : Lucidi V, Bohlok A, Liberale G, Bez M, Germanova D, Bouazza F, Demetter P, Larsimont D, Aftimos P, Smoll NR, Donckier V
Year : 2019
Journal : Eur J Surg Oncol

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Authors : Pondé N, Aftimos P, Piccart-Gebhart M
Year : 2019
Journal : Curr Treat Options Oncol

More publications »

Follow us!

Youtube

Exclusive images of the new Jules Bordet Institute!

Watch the video and discover the major project for the new Jules Bordet Institute. Magnificent images of the construction work on the   80,000 m² dedicated exclusively to cancer are accompanied by explanations on how the project was conceived to combine excellence of patient care with optimal well-being for patients and care staff.